HadosLab Blog

BPC-157, the peptide the human stomach makes to protect itself

In 1991, a group of researchers at the University of Zagreb identified in human gastric juice a protein capable of protecting cells from severe chemical damage. They isolated a fifteen-amino-acid fragment, gave it a technical name, BPC pentadecapeptide, Body Protection Compound, and began experimenting with it. Thirty years later, that small peptide derived from our own stomach has become one of the most researched regenerative compounds in the world and, at the same time, one of the most controversial from a regulatory point of view.

BPC-157 combines two things that rarely go together. On one hand, a serious scientific track record: more than 500 peer-reviewed publications, molecular mechanisms characterized down to signaling pathway level, and an extraordinarily favorable safety profile in animal models. On the other, a major imbalance in human evidence: the vast majority of studies come from a single Croatian group, clinical trials in people can be counted on one hand and its legal status varies radically from one country to another.

This article tries to honestly tell what BPC-157 is, what science really knows about it, what it still doesn't know and why it remains one of the most interesting and controversial molecules in current regenerative biology.

What exactly is BPC-157

BPC-157 is a synthetic pentadecapeptide. Literally, a chain of fifteen amino acids in a very specific sequence: glycine, glutamic acid, proline, proline, proline, alanine, glycine, histidine, lysine, arginine, aspartic, glutamic acid, valine, proline and closure. Its chemical formula is C62H98N16O22, with a molecular weight of 1,419 daltons and an assigned CAS number: 137525-51-0.

Although we call it synthetic, it is not a laboratory invention in the strict sense. The sequence was identified within a natural protein present in human gastric juice, named Body Protection Compound (BPC) for its protective effects on the digestive epithelium. Fragment 157 corresponds to a particular region of that parent protein, isolated by the group of Professor Predrag Sikiric and Sven Seiwerth at the Faculty of Medicine of Zagreb in the early 1990s.

What sets BPC-157 apart from the vast majority of research peptides is an unusual chemical property: stability in acidic medium. Most peptides degrade within minutes upon contact with human gastric juice. BPC-157, on the contrary, remains stable for more than 24 hours in that same environment. That robustness has allowed researchers to investigate its oral administration in addition to the injectable route, which is exceptional in this field.

The origin: a Croatian discovery from the 1990s

The story of BPC-157 begins with a clinical observation and forty years of work by the same research team. During the 1970s and 1980s, gastroenterology physiologists Andre Robert and Sandor Szabo had developed the concept of cytoprotection: the idea that certain substances could protect the gastric epithelium from chemical damage without needing to block acid secretion. It was a different way of understanding digestive protection, and it sparked the interest of researchers worldwide.

In Zagreb, Predrag Sikiric's team decided to look for whether human gastric juice itself contained endogenous cytoprotective substances. What they found was a large protein with protective effects. By fragmenting it and analyzing the most active sequences, they identified the pentadecapeptide that would come to be called BPC-157. The first publications appeared in Journal of Physiology and Pharmacology in the early nineties.

From there, Sikiric and his team turned BPC-157 into the central project of their laboratory for more than three decades. They have published on gastric ulcers, liver, heart, brain, bone, tendon, ligament, muscle, spinal cord, skin, eyes and autonomic nervous system. The internal coherence of the body of work is remarkable, although it raises a methodological problem we'll address later: around 80% of all PubMed-indexed publications on BPC-157 are signed by this same group.

How it works: the central role of nitric oxide

Unlike other peptides with a clearly identified specific receptor, BPC-157 appears to act on several cellular signaling pathways at once. It does not have a single characterized receptor, which has been one of the most debated points in the literature. What is well documented in animal models are the molecular pathways it activates.

The central, and most replicated, mechanism is the regulation of the nitric oxide (NO) system. Nitric oxide is a gaseous molecule with essential protective functions: it regulates blood pressure, maintains endothelial integrity, participates in healing and modulates inflammation. In excess it is toxic, in deficiency it generates circulatory problems. BPC-157 has a peculiar property: it modulates nitric oxide in both directions depending on context. In models where NO is low (due to pharmacological inhibition), BPC-157 restores it. In models where it is in pathological excess, it decreases it.

The peptide exerts that regulation fundamentally through the VEGFR2-Akt-eNOS axis, a molecular cascade that connects the vascular growth factor receptor with endothelial nitric oxide synthase. Activation of that pathway promotes the formation of new blood vessels (angiogenesis), improves perfusion of damaged tissues and accelerates repair processes that would normally take much longer.

Other pathways involved include the FAK-paxillin route in endothelial cell migration, ERK1/2 signaling in cell proliferation, the Egr-1 transcription factor and the PI3K/Akt axis in cellular survival under stress. Interaction with neurotransmission systems has also been documented: dopamine, serotonin and GABA in animal brain models, which would explain its observed effects on the gut-brain axis.

Regeneration of tendons, ligaments and muscle

The area where BPC-157 has generated the most interest in biohacking and sports medicine is the regeneration of musculoskeletal tissues. Tendons and ligaments are notoriously difficult structures to repair because they have very little vascularization. When they are injured, the lack of blood flow limits the arrival of nutrients, oxygen and repair cells to the damaged site.

In that exact area, BPC-157 appears to act by correcting the bottleneck. A study by Chang et al. published in Journal of Applied Physiology in 2011 demonstrated that the peptide promotes tendon healing through three mechanisms: tendon growth, cell survival and cell migration. Subsequent researchers have documented improved collagen organization, strengthening of injured tendons and ligaments, and reduction of recovery times after muscle tears.

A systematic review published in HSS Journal in 2025 analyzed 544 articles on BPC-157 between 1993 and 2024. The review confirmed the consistency of preclinical findings in musculoskeletal regeneration, but also pointed out the field's Achilles' heel: only one human clinical study met rigorous methodological criteria. The rest were animal models or anecdotal reports.

That limitation is important to qualify. The fact that there are no large-scale human clinical trials does not mean that the peptide doesn't work. It means that it has not yet been formally tested in humans with the rigor required by regulatory agencies. The preclinical evidence is promising; clinical evidence is pending.

The gut-brain axis and digestive protection

Given its gastric origin, it is logical that research on BPC-157 in the digestive system is especially deep. Animal models have documented protective effects against:

Gastric damage induced by non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin or indomethacin. BPC-157 reduces gastric ulcers caused by these drugs and accelerates their healing.

Ulcerative colitis and inflammatory bowel disease in murine models, where the peptide has shown effects comparable to reference drugs like 5-ASA in some parameters.

The healing of intestinal anastomoses after surgery, one of the critical points in human digestive surgery.

Beyond the intestine, studies by Sikiric's group have documented effects on the gut-brain axis: reversal of drug-induced dyskinesias, modulation of the dopaminergic system and protection of brain tissue in models of acute damage. It is a very interesting territory from a scientific point of view, although still exclusively preclinical.

Research protocols: doses and cycles

The research literature has consolidated approximate dosing guidelines that are repeated with variations between protocols. It is worth insisting that these are research protocols, not medical recommendations.

The most used subcutaneous injectable dose in recent literature is in the range of 250 to 500 micrograms twice daily, or 500 micrograms to 1 milligram once daily, with a typical duration of four to six weeks. Some protocols contemplate a more intensive loading phase the first two weeks followed by maintenance.

Cycling is important although less rigid than with GHK-Cu. The most cited protocols alternate four to six active weeks with similar rest periods. The subcutaneous route can be local (close to the injured area, especially for tendons and ligaments) or systemic in the abdomen.

The pharmacokinetics documented in rats and dogs by He et al. in Frontiers in Pharmacology (2022) revealed a very short plasma half-life, less than 30 minutes, and low bioavailability after intramuscular administration. These data suggest that the biological effect of the peptide does not depend on sustained plasma levels but on its rapid interaction with specific receptors or cellular targets during its passage through the organism.

The safety question

This is, probably, the most consistent argument in favor of BPC-157 in all its literature. Studies of acute and chronic toxicity in animal models have been extraordinarily clean.

In acute toxicity tests, Sikiric's team administered 2 grams per kilo intravenously in mice without observing any toxic or behavioral effect. That is equivalent, scaled to a 70-kilo human, to a dose of 140 grams, tens of thousands of times higher than any research dose used in practice. The LD1 (lethal dose for 1% of animals) was not reached in the experiments.

In chronic toxicity studies with repeated administration over months, the same researchers did not document significant alterations in hematological, biochemical, histopathological or behavioral parameters. The safety profile in rat, mouse and dog is, based on available data, exceptional.

Side effects reported in anecdotal human use are mild: temporary redness at the injection point, mild nausea, occasional dizziness and transient fatigue during the first doses. Nothing that deviates from the expected profile of any injectable compound.

There are, however, legitimate theoretical concerns. The stimulation of angiogenesis, beneficial in healing, could be problematic in people with undiagnosed pre-existing tumors. Sikiric's group has published studies arguing for anti-tumor effects of the peptide in experimental models, but caution with any pro-angiogenic compound in oncology remains reasonable.

Most studied combinations

In research literature and in the protocols of specialized clinics, BPC-157 frequently appears combined with other peptides that act on complementary pathways.

The most widespread combination is BPC-157 + TB-500. Both are regenerative peptides, but they act on different targets: BPC-157 on angiogenesis and the nitric oxide system, TB-500 (a fragment of thymosin beta-4) on actin cytoskeleton dynamics. Together they cover two key aspects of tissue repair that would be difficult to address with a single molecule.

The combination BPC-157 + TB-500 + GHK-Cu, dubbed in some circles as the Glow Stack, adds the copper peptide with its effect on extracellular matrix and gene expression. Theoretically it covers the three major fronts of regeneration: vascularization, structural cellular repair and tissue remodeling. The evidence of real synergy remains fundamentally preclinical.

Other documented combinations include BPC-157 + CJC-1295/Ipamorelin for protocols focused on growth and recovery, or BPC-157 + IGF-1 for specific muscle repair models.

Purity, COA and differences between formats

The distinction between two vials with the same BPC-157 label can be enormous. There are several critical factors to verify.

The first is the chemical form. Two main formats are commercialized in the market: BPC-157 "neat", which is the pure peptide without counter-salts, and BPC-157 trifluoroacetate, which is a salt of the peptide with trifluoroacetate. The salt is more stable and cheaper to produce, but in equivalent doses contains a slightly smaller amount of active peptide. Serious suppliers specify which format they sell.

The second is the minimum acceptable purity: 98%. Below that threshold it is considered a product unsuitable for rigorous research. High-end batches exceed 99%. Purity must be verified by high-performance liquid chromatography (HPLC) by an independent third-party laboratory, not by the manufacturer itself.

The third is the batch-specific Certificate of Analysis (COA), which must include peptide name, batch number, HPLC chromatogram with defined main peak, mass spectrometry confirming molecular identity, and analysis date. Generic COAs without batch number have no real scientific value.

The fourth is the cold chain. Lyophilized powder must be kept at -20°C for maximum stability. Reconstituted, it must be kept at 2-8°C and used within 30 days. A product that arrives at room temperature without adequate thermal packaging has suffered potential degradation.

The regulatory landscape in 2026

BPC-157 is going through one of the most turbulent regulatory moments in its history. It is worth distinguishing by geography.

In the United States, the FDA classified BPC-157 in September 2023 within Category 2 of bulk substances, which prohibited its preparation in compounding pharmacies. In February 2026, the Secretary of Health announced the reclassification of fourteen peptides, including BPC-157, to Category 1, and on April 15, 2026 the FDA formally published the removal of twelve peptides from the list of significant concerns. The FDA advisory committees have meetings scheduled in July 2026 for the formal evaluation of BPC-157 along with TB-500, MOTS-c and DSIP.

In Europe and Spain, BPC-157 is not authorized for human use in any format. Its legal commercialization is carried out exclusively under the research use only category, under the REACH and CLP regulations, with explicit labeling indicating that the product is for in vitro scientific research and not for human or veterinary consumption.

In professional sports, the World Anti-Doping Agency (WADA) includes BPC-157 in its list of prohibited substances of category S0 (non-approved substances) since 2022, both in and out of competition.

What we know and what we still don't

Anyone seriously approaching BPC-157 should do an exercise of intellectual honesty. There is a very solid body of preclinical evidence: hundreds of studies in animal models, characterized molecular mechanisms, favorable safety profiles and consistent effects on the regeneration of multiple tissues.

At the same time, there are limitations that should not be hidden. Most of the evidence comes from a single research center, human clinical trials are practically nonexistent, the plasma half-life is very short and raises questions about how the effects translate to real human use, and a specific receptor for the peptide has not been characterized.

None of those limitations invalidate the scientific interest of the compound. But they do force us to distinguish between what is proven and what remains hypothesis. BPC-157 could become an approved medicine in the coming years if clinical trials confirm what preclinical research suggests. It could also turn out to be less effective or more problematic in humans than animal models indicate.

Between the promise of the enthusiastic biohacker and the skepticism of the conservative regulator there is an honest middle ground: BPC-157 is one of the most interesting molecules in contemporary regenerative biology, with an exceptional preclinical base that deserves to be investigated rigorously in humans. The coming years will tell whether it lives up to its promises. In the meantime, it remains strictly a research compound, with everything that implies.